ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1815

Aneurysmal Lesions in Behcet’s Disease: A Report of 69 Cases from a Single Center

Jiaxin Zhou1, Jing Shi2, Xiuhua Wu2, JinJing Liu2 and Wenjie Zheng2, 1Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, 2Rheumatology, Peking Union Medical College Hospital, Beijing, China

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: To analyze the clinical features of patients with Behcet’s disease(BD) complicated with aneurysmal lesions.

Methods: We retrospectively reviewed the clinical data of patients with BD complicated with aneurysmal lesions in Peking Union Medical College Hospital from 1997 to 2017, the treatment and outcome were also studied.

Results: A total of 69 patients (56 male and 13 female) were included. The average period between BD onset and diagnosis of aneurysmal lesion was 5.4±5.5 years. A total of 120 arterial aneurysmal lesions were found, including 29 aneurysms, 68 pseudoaneurysms, 2 dissecting aneurysms, and 21 with uncertain classification. Thirty-four patients (49.3%) presented with two or more aneurysmal lesions. Abdominal aorta was the most common site of involvement (29/120), followed by pulmonary artery (20/120), femoral artery (15/120), thoracic aorta (11/20), coronary artery (10/120) and iliac artery (9/120). Swelling, pain and palpable masses in the affected artery’s area are major symptoms. Patients are more intended to have other types of vascular involvement. 48 (69.6%)patients were treated with large dose of glucocorticosteroids (prednisone at 0.8-1.2mg/kg per day, or equivalent doses) and 7 (10.1%) patients received methylprednisolone pulse therapy. Cyclophosphamide was the most commonly used immunosuppressant (60/69). Biological agents were administrated in 5 refractory cases. 40 patients received surgical therapy or interventional procedures. With a mean follow up of 3.8±3.5 years, 48 patients (69.6%) achieved clinical improvements with no newly-onset arterial lesions occurred, while 3 received a second interventional therapy, 5 died (mortality rate 7.2%).

Conclusion: Aneurysmal lesions are severe and life-threatening complications in BD patients. BD patients diagnosed with aneurysmal lesions should be further evaluated to detect possible associated vascular involvements or aneurysmal lesions at other sites. Achieving BD remission and performing surgical or interventional procedures are both important in the treatment of BD patients with aneurysmal lesions.


Disclosure: J. Zhou, None; J. Shi, None; X. Wu, None; J. Liu, None; W. Zheng, None.

To cite this abstract in AMA style:

Zhou J, Shi J, Wu X, Liu J, Zheng W. Aneurysmal Lesions in Behcet’s Disease: A Report of 69 Cases from a Single Center [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/aneurysmal-lesions-in-behcets-disease-a-report-of-69-cases-from-a-single-center/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/aneurysmal-lesions-in-behcets-disease-a-report-of-69-cases-from-a-single-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology